Taravana (High‑Altitude Cerebral Edema) – Comprehensive Guide

Overview

Taravana – a Samoan word meaning “to become crazy” – is the traditional name for what modern medicine calls **High‑Altitude Cerebral Edema (HACE)**. HACE is a life‑threatening form of altitude illness that results from swelling of brain tissue due to low‑oxygen (hypoxic) conditions at high elevations, usually above 2,500–3,000 meters (8,200–9,800 ft). While anyone ascending rapidly can develop HACE, it most commonly affects:

• Back‑packers, trekkers, and climbers who ascend >1,000 m (3,300 ft) in a single day.
• Workers and military personnel deployed to high‑altitude locations.
• Individuals with prior episodes of acute mountain sickness (AMS) or high‑altitude pulmonary edema (HAPE).

Exact prevalence is difficult to capture because HACE is rare, but epidemiological data from Himalayan expeditions estimate an incidence of **0.5–1 % of all high‑altitude trekkers**; the risk rises to **5–10 %** among those who develop severe AMS (Mayo Clinic).

Symptoms

Symptoms progress rapidly—often within 6–24 hours after arrival at altitude—and can be divided into early neurological signs and later, life‑threatening manifestations.

Early Neurological Signs

• Headache – persistent, throbbing, not relieved by usual analgesics.
• Ataxia – unsteady gait, difficulty walking in a straight line.
• Drowsiness or confusion – inability to concentrate, forgetfulness.
• Nausea/vomiting – often without a gastrointestinal cause.
• Loss of coordination – clumsiness, dropping objects.

Advanced / Severe Signs

• Altered mental status – ranging from irritability to coma.
• Severe ataxia – inability to stand or walk.
• Hallucinations or psychosis (the “taravana” phenomenon).
• Seizures – generalized or focal.
• Rapid, shallow breathing (hyperventilation) due to brainstem dysfunction.
• Elevated blood pressure and pulse from sympathetic surge.

Causes and Risk Factors

HACE is caused by **cerebral hypoxia leading to capillary leakage and brain swelling**. The exact cascade involves:

1. Reduced atmospheric pressure → lower partial pressure of oxygen.
2. Hypoxemia → vasodilation of cerebral vessels to increase blood flow.
3. Increased capillary permeability → fluid extravasation into brain interstitium.
4. Elevated intracranial pressure (ICP) → impaired neuronal function.

Key Risk Factors

• Rapid ascent – gaining >300 m (1,000 ft) per hour or >1,000 m per day.
• Previous AMS/HAPE – history of altitude illness triples the risk.
• High altitude above 3,500 m – risk rises exponentially.
• Age – younger adults (20‑40 yr) are most represented, likely due to more frequent climbing.
• Physical exertion – vigorous activity before full acclimatization.
• Dehydration, alcohol, or sedative use – exacerbate hypoxia.
• Pre‑existing neurological disease – e.g., migraines, epilepsy.

Diagnosis

Diagnosis is primarily clinical, based on history and physical exam, but supplemental tools can help confirm severity.

Clinical Assessment

• Lake Louise Scoring System – a validated questionnaire for AMS; scores ≥5 with neurological signs raise suspicion for HACE.
• Neurological exam – look for ataxia, nystagmus, altered consciousness.
• Oxygen saturation (SpO₂) – often <90 % at rest.

Imaging & Tests (when available)

• CT scan – can show brain edema, rule out hemorrhage.
• MRI – more sensitive for subtle edema.
• Transcranial Doppler ultrasound – may demonstrate increased cerebral blood flow.
• Blood gases – arterial PO₂ typically <60 mm Hg.

In remote mountain settings, imaging is seldom possible; therefore, **prompt clinical recognition** is critical.

Treatment Options

Time is of the essence. The first step is **immediate descent**—the single most effective intervention.

1. Descent

• Descend at least 500–1,000 m (1,600–3,300 ft) as rapidly as safely possible.
• If wheeled transport is unavailable, use a stretcher or carry the patient while maintaining airway patency.

2. Oxygen Therapy

• Administer 100 % supplemental O₂ via mask or non‑rebreather at 2–4 L/min.
• Goal SpO₂ > 93 %.

3. Medications

• Dexamethasone  – 4 mg IV/IM loading dose, then 4 mg every 6 h. Steroids reduce vasogenic edema and are the cornerstone pharmacologic therapy.
• Acetazolamide – 125–250 mg PO/IV every 12 h can aid acclimatization but is not a substitute for descent.
• Portable hyperbaric chambers – “Gamow bags” provide an equivalent of 2,500 m (8,200 ft) reduction in pressure; useful when descent is delayed.

4. Supportive Care

• Maintain a warm, calm environment to reduce metabolic demand.
• IV fluids (isotonic) if dehydrated, but avoid fluid overload.
• Monitor vitals, mental status, and SpO₂ continuously.

5. Advanced Interventions (hospital setting)

• Continuous positive airway pressure (CPAP) or mechanical ventilation if respiratory failure develops.
• Neuro‑critical care monitoring of intracranial pressure.
• Consider mannitol or hypertonic saline for refractory cerebral edema (under specialist supervision).

Living with Taravana (High‑Altitude Cerebral Edema)

For individuals who have experienced HACE, the focus is on safe return to high‑altitude activities and long‑term health.

Post‑episode Monitoring

• Complete medical evaluation within 2 weeks—neurological exam, possibly MRI.
• Screen for residual cognitive deficits (memory, attention) with simple bedside tests.

Long‑Term Management

• Gradual Re‑Acclimatization – Follow the “climb high, sleep low” rule; increase sleeping altitude by ≤300 m (1,000 ft) each night.
• Medication Prophylaxis – Acetazolamide 125 mg daily may be prescribed for the first 2–3 days of subsequent climbs.
• Fitness and Conditioning – Aerobic conditioning improves oxygen utilization; include interval training before future expeditions.
• Hydration & Nutrition – Aim for 2‑3 L of water daily; moderate carbohydrate intake to reduce respiratory demand.
• Psychological Support – Experiencing HACE can be traumatic; consider counseling if anxiety about future climbs develops.

Prevention

Prevention is achievable with careful planning and adherence to acclimatization principles.

• Ascend Gradually – No more than 300–500 m (1,000–1,600 ft) gain per day above 2,500 m; include a rest day every 3–4 days.
• “Climb High, Sleep Low” – Spend limited time at peak altitude but return to a lower sleeping elevation.
• Hydration – Drink 3–4 L of fluid per day; avoid alcohol and excessive caffeine.
• Acetazolamide Prophylaxis – 125 mg PO 1‑2 hours before ascent and then daily for the first 48–72 h at altitude (per CDC recommendations).
• Medication Review – Discontinue sedatives, antihistamines, and high‑dose opioids before climbing.
• Physical Conditioning – Build aerobic fitness 6–8 weeks before high‑altitude exposure.
• Use a Portable Hyperbaric Chamber – Carry a Gamow bag on expeditions above 4,000 m (13,000 ft).
• Education – All group members should be trained to recognize early AMS and HACE signs.

Complications

If untreated, HACE can rapidly become fatal due to:

• Brain herniation from uncontrolled intracranial pressure.
• Seizures leading to aspiration pneumonitis.
• Respiratory collapse secondary to brainstem dysfunction.
• Permanent neurologic deficits (cognitive impairment, ataxia).
• Multi‑system organ failure in prolonged severe hypoxia.

Mortality rates reported in historical Himalayan data range from **10 % to 30 %** when descent and treatment are delayed (>12 h) (Cleveland Clinic).

When to Seek Emergency Care

References

• Mayo Clinic. “High‑altitude illness.” https://www.mayoclinic.org
• CDC. “Travel health: High altitude.” https://wwwnc.cdc.gov
• NIH, National Institute of Neurological Disorders and Stroke. “High‑Altitude Cerebral Edema.” https://www.ninds.nih.gov
• Cleveland Clinic. “High‑Altitude Cerebral Edema (HACE).” https://my.clevelandclinic.org
• WHO. “Altitude Illness: Prevention and Management.” 2022 guidelines. https://www.who.int